Sequent Scientific Limited
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
What Sequent files
- Others49
- Important25
- Updates19
- Investor Meet18
- Board Meeting9
- PPTs5
**Business Performance & Key Financials:** SeQuent Scientific and Viyash Lifesciences merger received NCLT approval, positioning them as a major global animal health player. The combined entity showed robust Q2 FY26 performance with sales of ₹852.1 Cr (+16% YoY) and EBITDA surging to ₹189 Cr (+76% YoY), achieving a 22.2% margin....
Here's a concise, retail-friendly summary: **1. Business Performance:** SeQuent Scientific & Viyash Life Sciences delivered strong Q2 FY26 results. The combined entity reported revenues of ₹852.1 Cr, up 16% YoY, and EBITDA of ₹189 Cr, surging 76% YoY with margin expanding to 22.2%. SeQuent's standalone revenue grew 15% to ₹424...
1. Financial Highlights: SeQuent Scientific reported Q4 revenues of ₹4,017 million, up 11.2% YoY, with EBITDA rising 38.7% to ₹569 million and margin expansion of 280 bps to 14.2%. For FY25, revenues grew 13.3% to ₹15,514 million; EBITDA surged 86.6% to ₹1,993 million with margins improving 500 bps to 12.8%....
**Financial Highlights:** In Q3 FY25, SeQuent Scientific reported revenues of ₹3,908 mn, reflecting an 18.7% year-on-year growth, driven by a strong performance in both Formulations and API segments. The gross margin improved to 48.2%, aided by pricing strategies and operational efficiencies. EBITDA (pre-ESOP) stood at ₹494 mn, a substantial 63.8%...
SeQuent Scientific Limited continues to demonstrate robust growth in its performance for Q2 FY25, with revenues increasing 6.6% YoY to ₹3,686 million, driven by strong demand across key markets and a focus on formulation expansion. The company's first half saw an impressive overall revenue growth of 11.7% YoY. Gross margins...